Inteins as targets for potential antimycobacterial drugs

被引:32
|
作者
Paulus, H
机构
[1] Boston Biomed Res Inst, Watertown, MA 02472 USA
[2] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
关键词
inteins; mycobacterium tuberculosis; antimycobacterial drugs; protein splicing; RecA; DnaB; thymidylate synthase; DNA gyrase; CcdB toxin; green fluorescent protein; drug screening; drug targets; high throughput screening; review;
D O I
10.2741/1195
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein splicing is a self-catalyzed process mediated by inteins. The observation that inteins occur only in microorganisms and that they often interrupt genes that play an essential role in nucleic acid metabolism makes them attractive as potential antibacterial targets. Because mycobacteria are the only intein-containing bacteria associated with human hosts, inteins would represent highly specific antimycobacterial targets. In Mycobacterium tuberculosis, two important proteins of DNA repair and replication, RecA and DnaB, respectively, are interrupted by inteins that must be excised by protein splicing before these proteins can function. This review describes the screening systems for the detection of mutations or inhibitors that interfere with proteins splicing that have been developed and published to date. In three of these experimental system, inteins have been inserted into proteins that are toxic under certain conditions. Protein splicing therefore leads to conditional growth inhibition or cell death and its inhibition can be monitored in terms of bacterial growth. A fourth assay for protein splicing and its inhibition is based on purified proteins and measures the formation of Green Fluorescent Protein or its inhibition. The advantages of inteins as antimycobacterial targets are discussed.
引用
收藏
页码:S1157 / S1165
页数:9
相关论文
共 50 条
  • [1] Inteins as Drug Targets and Therapeutic Tools
    Tharappel, Anil Mathew
    Li, Zhong
    Li, Hongmin
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [2] Targets of Potential Radioprotective Drugs
    Hauer-Jensen, Martin
    Kumar, K. Sree
    CURRENT DRUG TARGETS, 2010, 11 (11) : 1351 - 1351
  • [3] PHARMACOLOGY OF THE ANTIMYCOBACTERIAL DRUGS
    PELOQUIN, CA
    MEDICAL CLINICS OF NORTH AMERICA, 1993, 77 (06) : 1253 - 1262
  • [4] SHORTAGES OF ANTIMYCOBACTERIAL DRUGS
    PELOQUIN, CA
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (10): : 714 - 714
  • [5] Allomaltol derivatives as Antimycobacterial agents: In vitro and in silico evaluations with potential protein targets
    Karakaya, Guelsah
    Hamdoun, Sami
    Oflaz, Ofcan
    Ozcelik, Berrin
    Aytemir, Mutlu Dilsiz
    ISTANBUL JOURNAL OF PHARMACY, 2024, 54 (03): : 446 - 455
  • [6] A Review of Antimycobacterial Drugs in Development
    Asif, Mohammad
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (13) : 1404 - 1418
  • [7] Serum concentrations of the antimycobacterial drugs
    Peloquin, CA
    CHEST, 1998, 113 (05) : 1154 - 1155
  • [8] Potential targets for the development of new antifungal drugs
    Su, Hao
    Han, Li
    Huang, Xueshi
    JOURNAL OF ANTIBIOTICS, 2018, 71 (12): : 978 - 991
  • [9] MicroRNA: Potential targets for the development of novel drugs?
    Wu W.
    Drugs in R & D, 2010, 10 (1) : 1 - 8
  • [10] Potential targets for the development of new antifungal drugs
    Hao Su
    Li Han
    Xueshi Huang
    The Journal of Antibiotics, 2018, 71 : 978 - 991